

# Government Advocacy and Public Policy

Our Government Advocacy & Public Policy team advances the goals of corporations, associations, governments, and other organizations by understanding their interests, applying practical governmental and political experience, and leveraging bipartisan relationships to ensure clients maximize their exposure and influence in Washington. Our lobbying practice efficiently leverages the deep-seated industry and technical experience held by the 1000+ lawyers across the firm to provide government advocacy plans that are tailored to each client's objectives. Our team includes well-known figures in public policy advocacy, each with decades of experience at the highest reaches of government, including practice co-chair Tom Spulak, Gov. Robert Ehrlich, Rep. Ander Crenshaw, Rep. Kendrick Meek, J.C. Boggs, Steve Kupka, Allison Kassir, George Crawford, Daniel R. Coats, and Daniel Lungren.

We also work closely with the firm's pre-eminent Congressional investigations team known for its representation of global brands as these corporations respond to high-profile and high-stakes Congressional investigations. Led by co-chair Dan Donovan, Sally Yates, and Ted Hester, the team effectively guides clients through the unique Congressional investigations experience while minimizing the legal and public relations risk these inquiries often pose.

Our team also provides counseling and representation on executive and congressional ethics as well as election law at the state and federal levels. Team members draw upon their extensive experience with highly technical congressional procedures which can be an invaluable factor in clients' legislative victories.

Cases & Deals
December 23, 2022

# Capability Lawyers



Daniel E. Lungren Washington, D.C.



Sally Q. Yates Atlanta



Jim C. Miller III Washington, D.C.



Kendrick B. Meek Washington, D.C.



Thomas J. Spulak Washington, D.C.



Theodore M. Hester (Ted) Washington, D.C.

# Recognition

Ranked #1 among 50 leading lobbying practices

NLJ "INFLUENCE 50"

Ranked Band 1 for Congressional Investigations

CHAMBERS USA 2022

They bring "value" and

K&S Advises Daniel Anderl Judicial Protection Project

February 29, 2016

King & Spalding Wins Federal Jury Trial in Key Off-Label Marketing Case on Behalf of Vascular Solutions Inc.

#### VIEW ALL

#### Insights

#### **CLIENT ALERT**

March 12, 2024

A Brief Overview of the Federal Rulemaking Process in the United States

#### **CLIENT ALERT**

Foreign Extortion Prevention Act (FEPA)

#### THOUGHT LEADERSHIP

December 4, 2023

Foreign Agents Registration Act: Enforcement in the Twenty-First Century

#### **VIEW ALL**

#### **Events**

## SPEAKING ENGAGEMENT

December 7, 2023

J.C. Boggs to Speak at Parliamentary Intelligence-Security Forum

#### **WEBINAR**

October 26, 2023

Navigating the Foreign Agents Registration Act (FARA): Where is DOJ Headed?

#### SPEAKING ENGAGEMENT

October 17, 2023

Eva Temkin to Speak at Fierce Biotech Summit

#### **VIEW ALL**

#### News

#### RECOGNITION

November 15, 2023

National Institute for Lobbying & Ethics Names Allison Kassir a Top Lobbyist

#### IN THE NEWS

November 1, 2023

Michael Taylor, Barbara Medrado, Christopher Hyner, Daniel Schneiderman, Eric Xie, Jamieson Greer, Katherine Vessels, Mark Wasden, Nick Paster, Stephen Orava and Stephen Vaughn counsel the Coalition for Fair Trade in Shopping Bags before the U.S. Department of Commerce, which announced preliminary countervailing tariffs on paper shopping bags from China and India "strong advocacy abilities to every engagement."

CHAMBERS USA

"Law Firm of the Year for Government Relations"

US NEWS & WORLD REPORT

"They deliver exceptional value" and "they work hard to understand our business."

CHAMBERS USA

"They have provided unparalleled access to policy and lawmakers."

CHAMBERS USA

"Strategic handling of a broad spectrum of regulatory, trade, and policy matters."

CHAMBERS USA

## IN THE NEWS

October 2, 2023

Israel Dahan, Ashley Parrish, John Shakow and Eva Temkin advise Novo Nordisk in its dispute against the U.S. Department of Health and Human Services over the Inflation Reduction Act's Medicare drug price negotiation provision

VIEW ALL